Ewing's sarcoma (ES) is characterized by specific chromosome translocations, the most common being t(11;22)(q24;q12). Additionally, other type of genetic abnormalities may occur and be relevant for explaining the variable tumour biology and clinical outcome. We have carried out a high-resolution array CGH and expression profiling on 25 ES tumour samples to characterize the DNA copy number aberrations (CNA) occurring in these tumours and determine their association with gene-expression profiles and clinical outcome. CNA were observed in 84% of the cases. We observed a median number of three aberrations per case. Besides numerical chromosome changes, smaller aberrations were found and defined at chromosomes 5p, 7q and 9p. All CNA were compiled to define the smallest overlapping regions of imbalance (SORI). A total of 35 SORI were delimited. Bioinformatics analyses were conducted to identify subgroups according to the pattern of genomic instability. Unsupervised and supervised clustering analysis (using SORI as variables) segregated the tumours in two distinct groups: one genomically stable (p3 CNA) and other genomically unstable (>3 CNA). The genomic unstable group showed a statistically significant shorter overall survival and was more refractory to chemotherapy. Expression profile analysis revealed significant differences between both groups. Genes related with chromosome segregation, DNA repair pathways and cell-cycle control were upregulated in the genomically unstable group. This report elucidates, for the first time, data about genomic instability in ES, based on CNA and expression profiling, and shows that a genomically unstable group of Ewing's tumours is correlated with a significant poor prognosis.
Introduction
Ewing's sarcoma (ES) is the second most common malignant bone tumour in children and young adults (Kovar, 1998) , and belongs to a wider group of neuroectodermal tumours known as ES Family of Tumours (Ushigome et al., 2002) . Their genetic hallmark is the presence of the reciprocal t(11;22)(q24;q12) translocation (Aurias et al., 1984; Mugneret et al., 1988) , or other less frequent variant translocations t(21;22)(q12;q12) and t(7;22)(p22;q12), and their morphology falls in the smallblue-round-cells category. The t(11;22) translocation leads to the fusion of the EWS gene on 22q12 with the FLI1 gene on 11q24, resulting in the formation and expression of the chimaeric transcript EWS-FLI1 (Delattre et al., 1992) that is thought to contribute to the pathogenesis of this tumour by modulating the expression of target genes.
Secondary chromosomal aberrations acquired in addition to the EWS rearrangements have been reported for many years based on conventional cytogenetic approaches. The most common correspond to trisomies of chromosome 8 (Mugneret et al., 1988) , 12 and gain of DNA sequences in 1q (Armengol et al., 1997) . The relation between these secondary changes and clinical outcome is quite controversial. Some authors refer that these aberrations may contribute to tumour progression and may serve as criteria for the aggressiveness of the disease (Zielenska et al., 2001) , although this relationship is not clearly established.
Development of new techniques as microarrays provides an opportunity to perform genome-wide analysis at different levels. Previous works have focused their research on array expression profiles of ES cell lines and primary tumours in order to identify tumour classification profiles, new EWS/FLI1 targets or to reveal distinct expression signatures associated to different outcomes (Khan et al., 2001; Ohali et al., 2004; Bandres et al., 2005; Mendiola et al., 2006) . A more recent genomic approach is the use of array-based comparative genomic hybridization (aCGH), which has been successfully used for the detection of genomic imbalances in human tumours (Pinkel and Albertson, 2005) in a most precise manner than chromosome-based conventional techniques. The patterns of copy number alterations identified by aCGH have been useful to differentiate tumours in more biologically and clinically relevant subtypes and the higher resolution has led to precise mapping of the boundaries of amplified and deleted regions indicating candidate genes relevant to cellular control pathways.
Considering that our current knowledge of clinical and biological features is still far from depicting a complete scenario of ES, we combined different approaches to search for novel genomic changes that occur during the development of this disease. In this report, we describe for the first time the results of an integrated genomic analysis using both array-based CGH and gene-expression profiling (GEP) in ES primary tumours.
Results and discussion
Genomic imbalance profiling A total of 23 primary and 2 recurrent ES tumours were analysed by whole genome array CGH (aCGH). A total of 21 tumours (84%) showed DNA copy number aberrations (CNA). The most frequent gains involved entire chromosomes 8 (56%), 12 (20%), 18 (12%), 20 (12%) and the short arm of chromosome 5 (5p) (20%). Most frequent losses affected entire chromosomes 10 (16%) and 19 (16%), and partial regions of chromosome arms 16q (16%) and 7q (25%). The summary of the CNA detected by aCGH is shown in Figure 1 . Conventional cytogenetics and chromosome-based CGH have been previously used to study genomic alterations in ES (Brisset et al., 2001; Ozaki et al., 2001; Hattinger et al., 2002) . Recurrent changes involving whole chromosome numeric aberrations were all confirmed in our series but aCGH also unveiled frequent chromosomal changes such as partial losses at 7q11.2 (5/25) or total/partial 5p gains (5/25) not previously described.
Application of aCGH facilitates the definition and limits of the aberrant regions that are present in a tumour sample, but it also provides a unique view of the overall stage of genomic instability. Our study shows that ES is a genomically heterogeneous disease at diagnosis. Data obtained by aCGH provided a global profile for each tumour that was further analysed in terms of genomic instability assessed by different parameters. First, we studied the extent of the genome affected by this instability, defined as the fraction (%) of the genome altered (FGA) by CNA. The median of FGA for all samples was 6% (with a wide range between 0 and 52%), similarly to what has been described for bladder carcinoma (Blaveri et al., 2005) . Other measures of genomic instability were taken into account such as the number of whole chromosome aberrations, the number of copy number transitions (CNT) within a chromosome, the presence and number of high-level amplifications or homozygous deletions (HD), and the number of chromosomes containing such transitions. The genomic instability profile of ES is summarized in Figure 2a and all studied parameters are provided in the Supplementary Table S1 . Chromosome numerical changes were seen in 17 cases (68%) and 15 cases (60%) showed CNT.
Of interest, four HD were detected in four cases: case number 22 showed two located at 7p22 and 7q36, case numbers 24 and 21 showed one at 9p21 and case number 7 showed one at 1p36 (Table 1 , validation by fluorescent in situ hybridization (FISH) is shown in Supplementary Figure S1 ). The HD region at 9p21 included the CDKN2A/B loci, confirming the role of this tumour suppressor gene in ES pathogenesis (Kovar, 1998) . Among the other HD, the 1p36 region contains a substantial numbers of putative tumour suppressor genes (Table 1) and it has been shown to be deleted in other tumours, such as neuroblastoma (Thompson et al., 2001) . On the other hand, high-level amplifications were not observed, in accordance with previous chromosome-based CGH studies.
To disclose genomic groups within the series, an unsupervised clustering analysis, using the presence of smallest overlapping regions of imbalance (SORI) as variable, was performed. According to this analysis (Figure 2b ), two main branches were segregated. One of them, named genomic unstable group, is characterized by a high number of aberrations (median number of 8 SORI per case, ranging from 4 to 18) while the other, the genomic stable group, only showed a small number of SORI (median number of 1 SORI per case, ranging from 0 to 3). We observed that trisomy 8, the most common secondary aberration in ES, was equally distributed in both branches, ruling out its potential role in the genomic instability segregation. We then decided to run a supervised clustering study of the genomic profiling in our ES series, using the genomic instability groups previously mentioned. A total of six regions, mainly located in chromosomes 12 and 19, showed a statistically significant association (Po0.05) with the highly unstable genomic group. The proposed genomic stability groups also differed in their genomic instability parameters, as defined previously (Supplementary Table S1 ). The group with a higher degree of genomic instability showed a higher number of CNT, of chromosomes with structural changes, of whole chromosome changes and a higher proportion of FGA than the group with lower number of changes. The latter is mainly composed of cases with the complete absence of aberrations or a small percentage of cases that presented numerical changes. Interestingly, the two recurrent tumours included in our series (numbers 9 and 14) belonged to the genetically unstable group, harbouring an elevated number of chromosome alterations.
Correlation of genomic instability with clinical outcome
Clinical data and follow-up were available from 20 patients with tumour samples at diagnosis (Supplementary  Table S2 ). We first analysed the relation between primary site location (axial vs peripheral), stage (localized vs metastatic), gain of chromosome 8 and overall genetic status (stable vs unstable) with clinical outcome by univariate survival analysis. As shown in Figure 3 , both stage and overall genetic status at diagnosis were negative predictors of overall survival (Po0.015 and Po0.017 respectively), while gain of chromosome 8 (the second more frequent chromosome alteration in ES) and primary site location were not associated with survival. By multivariate analysis the genomic instability status remained as the most significant independent prognostic factor (Figure 3 ). In addition, the patients from the genomic stable group showed a higher tendency to achieve complete remission during or after treatment than those from genomic unstable group (100 vs 62%, respectively, -square test). These data showed that genomic unstable group are more refractory to chemotherapy and, as a consequence, are associated to a poor prognosis.
Gene-expression profiling and genomic aberrations correlation
The definition of these two separated groups, based on the presence of CNA, led us to wonder about possible associations of CNA patterns with alterations in cellular pathways or genes involved in maintenance of genome instability. For that, we analysed the gene-expression profiles of both groups of tumours (unstable vs stable) to look for genes potentially related with the genomic instability profile. A group of 290 probes, corresponding to 265 unique genes, were shown to be differentially expressed between both groups of tumours (Po0.01) (Supplementary Table S3 ). A total of 10 of these genes that are known to be involved in DNA repair and cell-cycle control pathways (BLM, CCNB1, CDKN1C, CENPE, CHEK1, DBF4, FANCM, FGFR10P2, RGS1 and TOP2A) were additionally analysed by quantitative real-time RT-PCR in order to validate microarray data. As shown in Figure 4 , all genes analysed, except CDKN1C, were upregulated in the genomic unstable group and these differences were highly significant in six of these genes (Figure 4) .
A functional analysis of this group of genes was conducted using their annotation to gene ontology terms (see Supplementary methods for details). Genes implicated in mitosis and nuclear division and associated to pericentromeric chromosome regions and to the kinesin complex were significantly overrepresented in this group of genes (Table 2 and Supplementary Figures S2 and S3) . A second approach was conducted by using the Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) . This bioinformatics analysis compares experiments of genome-wide expression profiles from samples belonging to two classes (see Supplementary methods for details).
GSEA revealed statistically significant associations (false-discovery rate (FDR) o0.25) between the unstable genomic status and several Biocarta Pathways (www.biocarta.com). We found that most of differentially expressed genes in the unstable group were associated with DNA repair and cell-cycle control pathways such as ATRBRCA or RB (see Table 2 for details), association supported by the qRT-PCR results (Figure 4) . Thus, our data show that genomic instability in ES is associated with cell-cycle checkpoint pathways and a superior activity in the machinery of chromosome segregation and mitosis. If this particular expression profile is the cause or the consequence of the genomic instability is at the moment largely unknown.
In summary, we have shown for the first time a study combining the use of high-resolution genome-wide screening tools such as aCGH and GEP, in a series of ES primary tumours. Array-CGH allowed the definition of minor aberrations but also elucidated about the size and gene content of previously described alterations. With this study, we were able to segregate a homogenous tumour series into two groups based on genomic instability that are characterized by different patterns of gene-expression profiles and clinical outcome.
Materials and methods

Tumour samples and clinical data
Genetic and clinical data were collected from a series of 26 patients provided from Pathology Departments and Oncology Units of several Spanish Children's Hospitals and from Portuguese Institute of Oncology (IPO-Porto). A total of 24 samples were primary tumours obtained before any treatment and two of them were recurrent classified as ES harbouring the t(11;22) or t(21;22) based on immunohistologic examination and molecular detection (RT-PCR/cytogenetics) of fusion transcripts. All samples were processed for RNA and DNA extraction. 
CGH array
All samples were hybridized against Human Genome CGH 44k microarrays (Agilent Technologies, Palo Alto, CA, USA), spanning the entire human genome at a median resolution B75 kb. Hybridizations were done according to the manufacturer's protocols. A total of 25 out of 26 samples (tumour sample number 11 was excluded from all the studies) were considered for the study after filtering for quality of hybridization according to quality control parameter (DLRS) provided by the CGH Analytics v3.2.25 Software (Agilent Technologies). Microarray data were extracted with Feature Extraction Software v8.1. Data analysis and chromosome segmentation were performed with InSilicoArray CGH software-smoothing method (Eilers and de Menezes, 2005) , categorizing changes as 0, 1 or À1 indicating no change, gain or loss, respectively. Alterations in copy number with less than 5 consecutive probes and known copy number polymorphisms did not score as aberrations. ArrayCGH data have been deposited in NCBIs Gene-Expression Omnibus (GEO, http:// www.ncbi.nlm.nih.gov/geo/) and they are accessible through GEO Series temporary accession number 15303288 or freely at our ftp repository (www.cnio.es).
Expression array RNA was extracted from all samples. A total of 14 samples provided RNA suitable for hybridization (assessed with Agilent 2100 Bioanalyzer, Agilent). Microarray experiments were performed with CodeLink Human 20K (GE Healthcare, formerly Amersham Biosciences, Piscataway, NJ, USA) according to the manufactures' protocol and scanned at Genomic core facility of the Instituto de Investigaciones Biome´dicas (see Supplementary methods for more details). Microarray data have been deposited in NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession number GSE8303.
Definition of smallest overlapping regions of imbalance and FISH validation
Aberrant recurrent regions were defined as a sequence of altered probes common to a set of CGH profiles and SORI as a recurrent region that contains no smaller recurrent region (Rouveirol et al., 2006) . FISH assays were performed to validate the HD. UCSC genome browser (http://genome.ucsc. edu) was used to select the four BAC clones covering the 1p36 region: RP11-624A15, RP11-199O1, RP11-709H9 and RP11-473K14, and three BAC clones covering the 9p21 region: RP11-454C15, RP11-478M20 and RP11-615P15. The BACs were obtained from BACPAC Resource Center at the Children's Hospital Oakland Research (Institute in Oakland, CA, USA). Commercial centromeric probes for chromosomes 1 and 9 (Vysis Inc., DownersGrove, IL, USA) were used as controls. FISH assays were carried out as according to the manufacturer's instructions. FISH scoring of 1p36 and 9p21 regions fluorescence signals was carried out in each sample by counting the number of single copy gene and control probe signals in an average of 100 nuclei. HD status was considered as positive for a sample when the ratio test region/control was below 0.25 in >50% of tumour cells.
Bioinformatics and statistical analyses GEPAS Suite software (http://gepas.bioinfo.cipf.es/) was used for supervised clustering and gene annotation analysis of CGH data. Associations between genomic instability and other clinical parameters were assessed using Fisher's exact test for qualitative variables and Mann-Whitney test was used for continuous variables. All expression array data were analysed using CodeLink Expression Analysis Software (GE Healthcare). Expression data were normalized in R by the cyclic-loss method (Wu et al., 2005) , differential expression analysis was carried out using MeV (TIGR, Rockville, MD, USA) and Acuity 4.0 (Molecular Devices) softwares. Functional genomic analysis was performed using GSEA. Real-time quantitative RT-PCR First-strand cDNA was synthesized with the High capacity cDNA archive kit (Applied Biosystems, Foster city, CA, USA) from 1.5 mg. of total RNA in a 30 ml reaction. Real-time quantitative PCR was performed in a 10 ml reaction with 2.5 ml from 1/10 reverse transcription dilution using the Taqman Universal PCR Master Mix (Applied Biosystems) containing 0.2 mM of mRNA-specific primers and 0.1 mM Universal Probe Library probes (Roche Applied Science, Basel, Switzerland). Duplicate reactions were run on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Cycle threshold (C t ) values for each gene and for TATA binding protein (used as an internal housekeeping control) were calculated and exported to Excel spreadsheets for additional analysis. Relative expression was calculated as 2 ÀDCt , where DC t ¼ C tgene ÀC tTBP .
Statistical analysis
For a single comparison of two groups, the two-tailed Student's t-test was used. Univariate analysis between clinical or genetic parameters and outcome was performed using the log-rank test. Multivariate analysis was performed using Cox proportionalhazards regression. MedCalc software (Mariakerke, Belgium) and GraphPad Prism statistical software version 4.0 (GraphPad Software, San Diego, CA, USA) were used for statistical computations. Data are presented as mean7s.e.
